Overview

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
Phase:
Phase 2
Details
Lead Sponsor:
Avid Radiopharmaceuticals